You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 4, April 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (47)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Acne
 •Alert me on articles by topic

Effects of Subantimicrobial-Dose Doxycycline in the Treatment of Moderate Acne

Robert Skidmore, MD; Rodney Kovach, MD; Clay Walker, PhD; John Thomas, PhD; Mark Bradshaw, PhD; James Leyden, MD; Christopher Powala, BS; Robert Ashley, MA

Arch Dermatol. 2003;139:459-464.

Objective  To determine if treatment with subantimicrobial-dose (SD) doxycycline hyclate (20-mg tablets taken twice daily) improved clinical outcome, had any detectable effect on skin flora, led to overgrowth or colonization of skin by opportunistic pathogens, or resulted in an increase in antibiotic resistance by the surface skin microflora in patients with moderate acne compared with placebo.

Design  Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial.

Setting  Two university-based clinics.

Subjects  Adults (N = 51) with moderate facial acne.

Interventions  Patients were randomized to receive SD doxycycline (Periostat; CollaGenex Pharmaceuticals Inc, Newtown, Pa) or placebo twice daily for 6 months.

Main Efficacy Outcomes  Primary: changes from baseline in numbers of inflammatory, noninflammatory, and total lesions. Secondary: changes from baseline of individual counts of papules, pustules, and nodules and global assessments of clinical improvement by patient and physician.

Results  Forty patients completed 6 months of treatment. At 6 months, the SD doxycycline group had a significantly greater percent reduction in the number of comedones (P<.01), inflammatory and noninflammatory lesions combined (P<.01), and total inflammatory lesions (P<.05) than did the placebo group. They also had significantly greater improvement according to the clinician's global assessment (P = .03). There were no significant differences in microbial counts between groups and no evidence of change in antibiotic susceptibility or colonization by potential pathogens. The treatment was well tolerated.

Conclusions  Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.


From the Department of Medicine, Division of Dermatology (Dr Skidmore) and the College of Dentistry (Dr Walker), University of Florida, Gainesville; School of Medicine, Dermatology Section (Dr Kovach) and Department of Pathology, Health Sciences Center (Dr Thomas), West Virginia University, Morgantown; Covance Inc, Princeton, NJ (Dr Bradshaw); School of Medicine, Department of Dermatology, University of Pennsylvania, Philadelphia (Dr Leyden); and CollaGenex Pharmaceuticals Inc, Newtown, Pa (Messrs Powala and Ashley). The financial disclosure statement for these authors appears at the end of this article.


RELATED ARTICLE

Effect of Antibiotics on the Oropharyngeal Flora in Patients With Acne
Ross M. Levy, Eric Y. Huang, Daniel Roling, James J. Leyden, and David J. Margolis
Arch Dermatol. 2003;139(4):467-471.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acne is Not Associated with Yet-Uncultured Bacteria
Bek-Thomsen et al.
J. Clin. Microbiol. 2008;46:3355-3360.
ABSTRACT | FULL TEXT  

Acne Through the Ages: Case-Based Observations Through Childhood and Adolescence
Tom and Fallon Friedlander
CLIN PEDIATR 2008;47:639-651.
ABSTRACT  

Acne, Antibiotics, and Upper Respiratory Tract Infections
Chan and Shaw
Arch Dermatol 2005;141:1157-1158.
FULL TEXT  

Acne
James
NEJM 2005;352:1463-1472.
FULL TEXT  

Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases
Voils et al.
The Annals of Pharmacotherapy 2005;39:86-94.
ABSTRACT | FULL TEXT  

Treatment of Acne Vulgaris
Haider and Shaw
JAMA 2004;292:726-735.
ABSTRACT | FULL TEXT  

THE WHOLE PATIENT
Braswell
Journal of the American Dental Association 2003;134:1165-1166.
FULL TEXT  

Low-Dose Doxycycline for Moderate Acne
JWatch Pediatrics 2003;2003:14-14.
FULL TEXT  

Low-Dose Doxycycline for Moderate Acne
Journal Watch Dermatology 2003;2003:1-1.
FULL TEXT  

Low-Dose Doxycycline for Moderate Acne
JWatch General 2003;2003:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.